AC Immune SA (IMR.MU)

Compare

2.7050

-0.0050

(-0.18%)

As of 8:05:03 AM GMT+1. Market Open.

US Penny Stocks Spotlight: AC Immune And Two Others To Consider

As the U.S. equities market starts the new year with a continued slump, investors are closely monitoring opportunities that might emerge amidst broader market challenges. Penny stocks, often representing smaller or newer companies, remain an intriguing niche for those seeking growth potential beyond the well-trodden paths of large-cap investments. Despite their vintage name, these stocks can still offer surprising value and stability when backed by solid financial foundations.

Simply Wall St. 7 days ago

OBIO

ACIU

QSI
High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion.

Simply Wall St. 8 days ago

MGTX

ACIU

CDNA
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2

AC Immune (ACIU) SA announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome, DS. Targeting toxic forms of amyloid beta, ACI-24.060 is an active immunotherapy covering Abeta 1-15. The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. DS subjects in the interim analysis have been treated for up to one year, with no serious adverse events relat

TipRanks 30 days ago

ACIU
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ: A

GlobeNewswire last month

ACIU
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease vaccine like therapy.

Pharmaceutical Technology last month

ACIU
AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune (ACIU) announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are encouraged by these initial Phase 2 safety and immunogenicity data on our ACI-7104.056 active immunotherapy being studied in early Parkinson’s disease. The level of immu

TipRanks last month

ACIU
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, November 14, 2024 – AC Immune SA (NASD

GlobeNewswire last month

ACIU
AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take

GlobeNewswire last month

ACIU
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

It's been a good week for AC Immune SA ( NASDAQ:ACIU ) shareholders, because the company has just released its latest...

Simply Wall St. 2 months ago

ACIU
AC Immune: Q3 Earnings Snapshot

LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Tuesday reported third-quarter net income of $6.4 million, after reporting a loss in the same period a year earlier. The Lausanne, Switzerland-based company said it had net income of 6 cents per share. The results topped Wall Street expectations.

Associated Press Finance 2 months ago

ACIU
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and immunogenicity dataPrescreening rate for Phase 2b Retain trial of JNJ-2056 (ACI-35.030) in Alzheimer’s disease (AD) triggered CHF 24.6 million milestone under agreementJNJ-2056 received Fast Track designation from the U.S. FDACash of CHF 157.9 million at the end of September, plus the CHF 24.6 million milestone

GlobeNewswire 2 months ago

ACIU
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%

Key Insights AC Immune's significant individual investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 2 months ago

ACIU
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in SeptemberPotentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic ADFDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD Lausanne, Switzerland, September 17, 2024 – AC Immune SA (NASDAQ

GlobeNewswire 3 months ago

ACIU
FDA grants fast track designation to Life Molecular Imaging’s tau PET diagnostic

Life Molecular Imaging’s PI-2620 tracer compound has received FDA fast track designation across three neurodegenerative conditions.

Medical Device Network 4 months ago

ACIU
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMIThis Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degenerationFollows two previous Fast Track designations for ACI-35.030 and ACI-24.060 active immunotherapiesAffirms AC Immune’s leadership and commitment to bringing precision medici

GlobeNewswire 4 months ago

ACIU
The past three years for AC Immune (NASDAQ:ACIU) investors has not been profitable

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of AC Immune SA...

Simply Wall St. 4 months ago

ACIU
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

ACIU
AC Immune: Q2 Earnings Snapshot

LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Tuesday reported a loss of $25.2 million in its second quarter. On a per-share basis, the Lausanne, Switzerland-based company said it had a loss of 25 cents. The results did not meet Wall Street expectations.

Associated Press Finance 5 months ago

ACIU
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial in Alzheimer’s disease (AD) on track with enrolment expectationsACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson’s disease (PD) on track for safety and immunogenicity inte

GlobeNewswire 5 months ago

ACIU
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or sma

GlobeNewswire 5 months ago

ACIU

Performance Overview

Return	IMR.MU	S&P 500
YTD	+4.44%	-1.41%
1-Year	-37.89%	+22.44%
3-Year	-35.66%	+24.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AC Immune SA (IMR.MU)

US Penny Stocks Spotlight: AC Immune And Two Others To Consider

High Growth Tech Stocks in the United States

AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit

AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

AC Immune: Q3 Earnings Snapshot

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

FDA grants fast track designation to Life Molecular Imaging’s tau PET diagnostic

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

The past three years for AC Immune (NASDAQ:ACIU) investors has not been profitable

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune: Q2 Earnings Snapshot

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Performance Overview